CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients

2019155 citationsJournal Article

Authors

Paul J. Pockros · Scripps Clinic

Michael Fuchs · Hunter Holmes McGuire VA Medical Center

B. Freilich · Kansas City Research Institute

Eugene R. Schiff · University of Miami

Anita Kohli · Institute for Liver Health

Eric Lawitz · The University of Texas Health Science Center at San Antonio

Paul Hellstern

Abstract

The CONTROL study showed that OCA-induced increases in LDLc in patients with NASH were mitigated with atorvastatin. The combination of OCA and atorvastatin was generally safe and well tolerated (NCT02633956).

Topics & Keywords

Liver Disease Diagnosis and Treatment Drug Transport and Resistance Mechanisms Liver Diseases and Immunity

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Liver International

Volume 39, Issue 11, pp. 2082-2093

DOI: 10.1111/liv.14209

Field-Weighted Citation Impact: 15.29